Table 1 Clinical and Pathological features of ovarian cancer patients according to pathogenic and likely pathogenic BRCA1 and BRCA2 variants
Characteristics | BRCA 1/2 wt (N = 125) | BRCA 1/2 mut (N = 33) | p |
|---|---|---|---|
Median age at diagnosis in years (IQR) | 54.44 (42.7–67.7) | 60.65 (43.8–67.2) | 0.946 |
Time between diagnosis and genetic testing in months (IQR) | 23.91 (10.75–45.15) | 18.95 (8.86–39.77) | 0.390 |
Histology | 0.109 | ||
Serous | 83 (66.4) | 27 (81.8) | |
Non-serous | 40 (32.0) | 6 (18.2) | |
Missing | 2 (1.2) | 0 (0) | |
FIGO stage | 0.288 | ||
I/II | 29 (23.2) | 5 (15.1) | |
III/IV | 86 (68.8) | 26 (78.8) | |
Missing | 10 (8.0) | 2 (6.1) | |
Personal history of breast cancer | 0.001 | ||
Positive | 4 (3.2) | 8 (24.2) | |
Negative | 105 (84.0) | 22 (66.6) | |
Missing | 16 (12.8) | 3 (9.1) | |
Family history for breast and/or ovarian cancer | 0.115 | ||
Positive (first and/or second degree relatives) | 55 (44.0) | 20 (60.6) | |
Negative | 54 (43.2) | 11 (33.3) | |
Not completely Known/ Unknown | 16 (12.8) | 2 (9.1) | |
Median pretreatment CA-125 (IQR) | 436.5 (117.5–1163.0) | 681.5 (126.5–2062.5) | 0.351 |
Treatment | 0.414 | ||
First-line | 65 (52.0) | 19 (57.7) | |
Platinum-sensitive | 41 (32.8) | 11 (33.3) | |
Platinum-resistant | 13 (10.4) | 1 (3.0) | |
Unknown | 6 (4.8) | 2 (6.0) |